MedTrace Logo

GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases

NCT07021209 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-09-15

No results posted yet for this study

Summary

This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune diseases.

Conditions

  • Neurological Autoimmune Diseases

Interventions

BIOLOGICAL

GT719 Injection

GT719 Injection

Sponsors & Collaborators

  • Tongji Hospital

    collaborator OTHER

  • Grit Biotechnology

    lead INDUSTRY

Principal Investigators

  • Wei Wang · Tongji Hospital

  • Daishi Tian · Tongji Hospital

  • Chuan Qin · Tongji Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-14
Primary Completion
2028-01-13
Completion
2028-01-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07021209 on ClinicalTrials.gov